Shanghai RAAS Blood Products Co., Ltd.

XSEC:002252 Stock Report

Market Cap: CN¥46.0b

Shanghai RAAS Blood Products Past Earnings Performance

Past criteria checks 2/6

Shanghai RAAS Blood Products has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 27.8% per year. Shanghai RAAS Blood Products's return on equity is 5.9%, and it has net margins of 21.9%.

Key information

19.0%

Earnings growth rate

16.1%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate27.8%
Return on equity5.9%
Net Margin21.9%
Next Earnings Update18 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shanghai RAAS Blood Products makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002252 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248,3431,830771232
30 Jun 248,3161,781780193
31 Mar 247,9571,818702178
31 Dec 237,9641,779707174
30 Sep 237,5512,064715176
30 Jun 237,1742,058722168
31 Mar 236,9452,051724157
31 Dec 226,5671,880722146
30 Sep 226,1931,502715153
30 Jun 225,8261,445693149
31 Mar 225,1191,416646142
31 Dec 214,2881,295605129
30 Sep 213,7701,624611138
30 Jun 213,2081,537574129
31 Mar 212,8841,439555130
31 Dec 202,7621,324533130
30 Sep 202,7071,098524104
30 Jun 202,59789254799
31 Mar 202,73270060899
31 Dec 192,585608632102
30 Sep 192,311380756107
30 Jun 192,141-258754102
31 Mar 192,071-610681102
31 Dec 181,804-1,51864096
30 Sep 181,869-1,39748989
30 Jun 182,021-720348139
31 Mar 181,843-76364115
31 Dec 171,92883634997
30 Sep 172,1771,32034765
30 Jun 172,1551,6734060
31 Mar 172,2411,5233660
31 Dec 162,3261,6133650
30 Sep 162,1381,5083810
30 Jun 162,2351,2593860
31 Mar 162,1441,3763850
31 Dec 152,0131,4423870
30 Sep 151,9861,3593210
30 Jun 151,5941,1692900
31 Mar 151,4228232580
31 Dec 141,3205112360
30 Sep 148603151800
30 Jun 147442311640
31 Mar 146571871590

Quality Earnings: 002252 has high quality earnings.

Growing Profit Margin: 002252's current net profit margins (21.9%) are lower than last year (27.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002252's earnings have grown by 19% per year over the past 5 years.

Accelerating Growth: 002252's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002252 had negative earnings growth (-11.3%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).

Return on Equity

High ROE: 002252's Return on Equity (5.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 10:03
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai RAAS Blood Products Co., Ltd. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Pei ChengChina Galaxy Securities Co., Ltd.
Shanshan LiChina Merchants Securities Co. Ltd.